Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome.
Adult
Bacteria
/ classification
Breath Tests
Case-Control Studies
Dysbiosis
/ diagnosis
Feces
/ microbiology
Female
Humans
Intestine, Small
/ microbiology
Irritable Bowel Syndrome
/ microbiology
Male
Mucous Membrane
/ microbiology
Phylogeny
RNA, Bacterial
/ genetics
RNA, Ribosomal, 16S
/ genetics
Sequence Analysis, DNA
/ methods
Severity of Illness Index
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 01 2020
17 01 2020
Historique:
received:
05
07
2019
accepted:
30
12
2019
entrez:
19
1
2020
pubmed:
19
1
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Altered bacterial composition and small intestinal bacterial overgrowth (SIBO) may be associated with irritable bowel syndrome (IBS). This study aimed to determine the fecal and mucosa-associated bacterial composition along the gastrointestinal (GI) tract and to assess SIBO in IBS. Bacterial composition of feces, and mucosa of the duodenum and sigmoid colon was determined by 16S rRNA-amplicon-sequencing. SIBO was evaluated by bacterial culture of duodenal aspirate, glucose and lactulose breath tests. Mucosal antibacterial gene expression was assessed by PCR Array. The bacterial profiles of feces and the mucosa of sigmoid colon, but not duodenum, differed between IBS patients (n = 17) and HS (n = 20). The IBS specific bacterial profiles were linked to the colonic antibacterial gene expression. Fecal bacterial profile differed between IBS subtypes, while the mucosa-associated bacterial profile was associated with IBS symptom severity and breath tests results at baseline (H
Identifiants
pubmed: 31953505
doi: 10.1038/s41598-020-57468-y
pii: 10.1038/s41598-020-57468-y
pmc: PMC6969101
doi:
Substances chimiques
RNA, Bacterial
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
593Références
Whitehead, W. E., Palsson, O. S. & Simren, M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol 11, 281–283, https://doi.org/10.1080/17474124.2017.1292130 (2017).
doi: 10.1080/17474124.2017.1292130
pubmed: 28276814
Chen, B., Kim, J. J., Zhang, Y., Du, L. & Dai, N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol, https://doi.org/10.1007/s00535-018-1476-9 (2018).
Pimentel, M. et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis 63, 450–452 (2004).
doi: 10.1136/ard.2003.011502
Scarpellini, E. et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr 155, 416–420, https://doi.org/10.1016/j.jpeds.2009.03.033 (2009).
doi: 10.1016/j.jpeds.2009.03.033
pubmed: 19535093
Ding, X. W. et al. The relationship between small intestinal bacterial overgrowth and irritable bowel syndrome. Eur Rev Med Pharmacol Sci 21, 5191–5196, https://doi.org/10.26355/eurrev_201711_13839 (2017).
doi: 10.26355/eurrev_201711_13839
pubmed: 29228433
Bures, J. et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 16, 2978–2990 (2010).
doi: 10.3748/wjg.v16.i24.2978
Stewart, E. J. Growing unculturable bacteria. J Bacteriol 194, 4151–4160, https://doi.org/10.1128/JB.00345-12 (2012).
doi: 10.1128/JB.00345-12
pubmed: 22661685
pmcid: 3416243
Ford, A. C., Spiegel, B. M., Talley, N. J. & Moayyedi, P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 7, 1279–1286, https://doi.org/10.1016/j.cgh.2009.06.031 (2009).
doi: 10.1016/j.cgh.2009.06.031
pubmed: 19602448
Jeffery, I. B. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61 (2012).
Tap, J. et al. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology 152, 111–123 e118, https://doi.org/10.1053/j.gastro.2016.09.049 (2017).
doi: 10.1053/j.gastro.2016.09.049
pubmed: 27725146
Sundin, J. et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 41, 342–351 (2015).
doi: 10.1111/apt.13055
Bennet, S. M. P. et al. Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. Neurogastroenterol Motil, e13468, https://doi.org/10.1111/nmo.13468 (2018).
Giamarellos-Bourboulis, E. et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol 50, 1076–1087, https://doi.org/10.3109/00365521.2015.1027261 (2015).
doi: 10.3109/00365521.2015.1027261
pubmed: 25865706
Dlugosz, A. et al. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep 5, 8508, https://doi.org/10.1038/srep08508 (2015).
doi: 10.1038/srep08508
pubmed: 25687743
pmcid: 4330528
Chu, H. et al. Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines. Gastroenterol Res Pract 2016, 3230859, https://doi.org/10.1155/2016/3230859 (2016).
doi: 10.1155/2016/3230859
pubmed: 27379166
pmcid: 4917718
Hillman, E. T., Lu, H., Yao, T. & Nakatsu, C. H. Microbial Ecology along the Gastrointestinal Tract. Microbes Environ 32, 300–313, https://doi.org/10.1264/jsme2.ME17017 (2017).
doi: 10.1264/jsme2.ME17017
pubmed: 29129876
pmcid: 5745014
Lacy, B. E. et al. Bowel Disorders. Gastroenterology 150, 1393–1407 (2016).
doi: 10.1053/j.gastro.2016.02.031
Vandeputte, D. et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 65, 57–62, https://doi.org/10.1136/gutjnl-2015-309618 (2016).
doi: 10.1136/gutjnl-2015-309618
pubmed: 26069274
Diether, N. E. & Willing, B. P. Microbial Fermentation of Dietary Protein: An Important Factor in Diet(-)Microbe(-)Host Interaction. Microorganisms 7, https://doi.org/10.3390/microorganisms7010019 (2019).
Ohman, L., Tornblom, H. & Simren, M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 12, 36–49, https://doi.org/10.1038/nrgastro.2014.200 (2015).
doi: 10.1038/nrgastro.2014.200
pubmed: 25446728
Guo, R., Chen, L. H., Xing, C. & Liu, T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth. https://doi.org/10.1016/j.bja.2019.07.026 (2019).
doi: 10.1016/j.bja.2019.07.026
pubmed: 31551115
Mancabelli, L. et al. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol Ecol 93, https://doi.org/10.1093/femsec/fix153 (2017).
West, C. E. et al. Gut microbiome and innate immune response patterns in IgE-associated eczema. Clin Exp Allergy 45, 1419–1429, https://doi.org/10.1111/cea.12566 (2015).
doi: 10.1111/cea.12566
pubmed: 25944283
Flint, H. J., Bayer, E. A., Rincon, M. T., Lamed, R. & White, B. A. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 6, 121–131, https://doi.org/10.1038/nrmicro1817 (2008).
doi: 10.1038/nrmicro1817
pubmed: 18180751
pmcid: 18180751
Sundin, J., Rangel, I., Kumawat, A. K., Hultgren-Hörnquist, E. & Brummer, R. J. Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. Scand J Gastroenterol. 49 (2014).
Bennet, S. M. P. et al. Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome. American Journal of Gastroenterology 111, 1165–1176 (2016).
doi: 10.1038/ajg.2016.223
Gasbarrini, A. et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 29(Suppl 1), 1–49, https://doi.org/10.1111/j.1365-2036.2009.03951.x (2009).
doi: 10.1111/j.1365-2036.2009.03951.x
pubmed: 19344474
Rezaie, A. et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol 112, 775–784, https://doi.org/10.1038/ajg.2017.46 (2017).
doi: 10.1038/ajg.2017.46
pubmed: 28323273
pmcid: 5418558
Simrén, M. & Stotzer, P. O. Use and abuse of hydrogen breath tests. Gut 55, 297–303 (2006).
doi: 10.1136/gut.2005.075127
Ouwerkerk, J. P., de Vos, W. M. & Belzer, C. Glycobiome: bacteria and mucus at the epithelial interface. Best Pract Res Clin Gastroenterol 27, 25–38, https://doi.org/10.1016/j.bpg.2013.03.001 (2013).
doi: 10.1016/j.bpg.2013.03.001
pubmed: 23768550
Booijink, C. C. et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol 12, 3213–3227 (2010).
doi: 10.1111/j.1462-2920.2010.02294.x
Matto, J. et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome–a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43, 213–222 (2005).
doi: 10.1016/j.femsim.2004.08.009
Maukonen, J. et al. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 55, 625–633, https://doi.org/10.1099/jmm.0.46134-0 (2006).
doi: 10.1099/jmm.0.46134-0
pubmed: 16585652
Jalanka-Tuovinen, J. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63, 1737–1745 (2014).
doi: 10.1136/gutjnl-2013-305994
Aziz, I., Tornblom, H., Palsson, O. S., Whitehead, W. E. & Simren, M. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. Am J Gastroenterol 113, 1017–1025, https://doi.org/10.1038/s41395-018-0074-z (2018).
doi: 10.1038/s41395-018-0074-z
pubmed: 29880963
Longstreth, G. F. et al. Functional bowel disorders. Gastroenterology 130, 1480–1491, https://doi.org/10.1053/j.gastro.2005.11.061 (2006).
doi: 10.1053/j.gastro.2005.11.061
pubmed: 16678561
Castiglione, F. et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol 31, 63–66 (2000).
doi: 10.1097/00004836-200007000-00015
Park, J. H. et al. The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome. Gut Liver 3, 174–179, https://doi.org/10.5009/gnl.2009.3.3.174 (2009).
doi: 10.5009/gnl.2009.3.3.174
pubmed: 20431742
pmcid: 2852716
Ghoshal, U. C., Srivastava, D., Ghoshal, U. & Misra, A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol 26, 753–760, https://doi.org/10.1097/MEG.0000000000000122 (2014).
doi: 10.1097/MEG.0000000000000122
pubmed: 24849768
Rhodes, J. M., Middleton, P. & Jewell, D. P. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol 14, 333–336 (1979).
doi: 10.3109/00365527909179892
Hugerth, L. W. et al. A comprehensive automated pipeline for human microbiome sampling, 16S rRNA gene sequencing and bioinformatics processing. bioRxiv Mars 21 (2018).
Umetrics. SIMCA-P and Multivariate Analysis FAQ. Version 1.01. Accessed 26 September (2016).
Eriksson, L., Kettaneh-Wold, N., Trygg, J., Wikström, C. & Wold, S. (Umetrics Inc, 2006).